Overview

Study of First Line Treatment of Chronic Graft Versus Host Disease With the Association of Ciclosporine, Corticosteroids and Rituximab (Protocol R-GVHD)

Status:
Completed

Trial end date:
2014-03-01

Target enrollment:

Participant gender:

Summary

The main objective of the study is to improve the response rate (complete and partial remission) at 12 months after diagnosis of chronic Chronic Graft Versus Host Disease (GVHD) and treatment with the combination of ciclosporine, prednisone and Rituximab as first line treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Nantes University Hospital

Treatments:

Cyclosporine
Cyclosporins
Rituximab